Abstract

BACKGROUND: Successful chemotherapy of lung cancer relies largely on the use of a good drug delivery system (DDS). We successfully constructed a hybrid DDS comprised of hydroxyapatite (HAP) nanoparticles and bovine serum albumin (BSA).

MATERIAL AND METHODS: The HAP nanoparticles were selected as the core to encapsulate the anticancer drug doxorubicin (DOX), followed by surface modification of BSA as a stabilizer and shielding corona to finally prepare the hybrid DDS (BSA/HAP/DOX).

RESULTS: The following characterizations revealed that BSA/HAP nanoparticles have high stability, high biocompatibility, and good DOX-loading capability to meet in vivo applications. Moreover, BSA/HAP/DOX can enhance the cellular uptake of drug in A549 cells (lung cancer cells). Most importantly, BSA/HAP had better in vivo tumor targetability than bare HAP nanoparticles, which resulted in stronger anticancer efficacy both in vitro and in vivo than free DOX or HAP/DOX, and greatly decreased the adverse effects of free DOX.

CONCLUSIONS: Our hybrid DDS shows potential to be applied in more advanced application of cancer therapy.

Keywords: Hydroxyapatites, Nanoparticles, A549 cells, Antineoplastic Agents, China, Doxorubicin, Drug Carriers, Drug Delivery Systems, Durapatite, Serum Albumin, Bovine